z-logo
open-access-imgOpen Access
The Floppy Iris Syndrome - What Urologists and Ophthalmologists Need to Know
Author(s) -
Faruquz Zaman,
Christian Bach,
Islam Junaid,
Athanasios Papatsoris,
Jhumur Pati,
Junaid Masood,
Noor Buchholz
Publication year - 2012
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1159/000338861
Subject(s) - tamsulosin , medicine , lower urinary tract symptoms , cataract surgery , glaucoma , urology , ophthalmology , hyperplasia , prostate , cancer
Benign prostatic hyperplasia (BPH) and cataract formation are common in older people. Medical management of symptomatic BPH is often preferred to surgical treatment as surgery increases the risk of morbidities, whereas, surgery is the main form of treatment to restore sight in patient with cataract. The clinical treatment of BPH is either alpha-1 adrenergic antagonist alone or combination of alpha reductase inhibitor and alpha adrenergic receptor (AR) antagonist. There are four alpha-AR antagonists currently available to treat BPH. The uroselective alpha-blocker tamsulosin is the most commonly used drug among all. Studies showed that the majority of the patients who develop intraoperative floppy iris syndrome (IFIS) were on tamsulosin. Women are more likely to develop cataract than men and some recent studies showed that tamsulosin is effective in treating female lower urinary tract symptoms and thereby can cause IFIS during cataract surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom